Capricor Therapeutics Faces Legal Action
Capricor Therapeutics, Inc. (NASDAQ: CAPR) recently attracted attention due to a pending securities class action lawsuit filed on behalf of its shareholders. This development is pivotal for those who invested in the company during the specified timeframe.
Understanding the Allegations
The lawsuit stems from allegations concerning Capricor's disclosures regarding its lead cell therapy candidate, deramiocel. Shareholders are encouraged to pay close attention to the ramifications of these allegations, as they may affect the overall value of their investments. The complaint highlights that the company provided misleading information about the progress and approval of deramiocel for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD).
Key Claims Against Capricor
Defendants, connected to Capricor, supposedly omitted vital information when communicating with investors, specifically those data points from the Phase 2 HOPE-2 trial study. The misleading statements allowed the company to inflate its stock price artificially, ultimately leading to significant losses for those who relied on this information.
Impacts of the Complete Response Letter
On July 11, 2025, a significant turning point occurred when Capricor released a press statement indicating that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA). The letter stated that Capricor's Biologics License Application (BLA) for deramiocel did not meet the required standards for substantial evidence of effectiveness. Furthermore, it called for additional clinical data to support the application.
Stock Price Implications
Following the announcement of the CRL, Capricor’s stock price plummeted from $11.40 on July 10, 2025, to $7.64 the next day. This decline raised alarm bells among investors, reinforcing the importance of the lawsuit as shareholders seek accountability and potential recovery for their losses.
Important Information for Shareholders
Capricor shareholders who acquired shares during the aforementioned class period are encouraged to register their claim in the ongoing legal proceedings. The deadline for making a lead plaintiff application is September 15, 2025, providing a limited window for affected shareholders to take action.
Steps to Register for the Class Action
To participate in the class action, shareholders should complete a registration form to secure their interests. This process is crucial to ensure that they are included in this legal recourse without any cost or obligation. The Gross Law Firm, known for its efforts in protecting investor rights, is leading the charge in this matter.
Why Choose the Gross Law Firm?
The Gross Law Firm prides itself on being a nationally recognized entity specializing in class action lawsuits. Their mission focuses on championing the rights of investors harmed by deceitful business practices. They aim to uphold responsible corporate governance and advocate for fair treatment of investors who have suffered financial losses due to misinformation.
Contact Information
For further inquiries, shareholders can reach out to The Gross Law Firm at:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
Frequently Asked Questions
What is the nature of the allegations against Capricor?
The allegations pertain to misleading statements made by Capricor regarding the effectiveness and approval status of deramiocel, its lead drug candidate.
Who can participate in the class action?
Shareholders who acquired CAPR shares during the defined class period are eligible to participate in the class action.
What is the deadline for filing as a lead plaintiff?
The deadline to apply to be a lead plaintiff in this class action is September 15, 2025.
How can shareholders register for the class action?
Shareholders can register by completing an online claim form established by the law firm handling the case.
What does the Gross Law Firm do?
The Gross Law Firm specializes in class action lawsuits, advocating for investors' rights and seeking recovery for losses from deceptive business practices.
